Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia

Research output: Contribution to journalReview article

Abstract

Introduction: Outcomes for the majority of patients with acute myeloid leukemia (AML) remain poor. Over the past decade, significant progress has been made in the understanding of the cytogenetic and molecular determinants of AML pathogenesis. One such advance is the identification of recurring mutations in the FMS-like tyrosine kinase 3 gene (FLT3). Currently, this marker, which appears in approximately one-third of all AML patients, not only signifies a poorer prognosis but also identifies an important target for therapy. FLT3 inhibitors have now undergone clinical evaluation in Phase I, II and III clinical trials, as both single agents and in combination with chemotherapeutics. Unfortunately, to date, none of the FLT3 inhibitors have gained FDA approval for the treatment of patients with AML. Yet, several promising FLT3 inhibitors are being evaluated in all phases of drug development.Areas covered: This review aims to highlight the agents furthest along in their development. It also focuses on those FLT3 inhibitors that are being evaluated in combination with other anti-leukemia agents.Expert opinion: The authors believe that the field of research for FLT3 inhibitors remains promising, despite the historically poor prognosis of this subgroup of patients with AML. The most promising areas of research will likely be the elucidation of the mechanisms of resistance to FLT3 inhibitors, and development of potent FLT3 inhibitors alone or in combination with hypomethylating agents, cytotoxic chemotherapy or with other targeted agents.

Original languageEnglish (US)
Pages (from-to)943-954
Number of pages12
JournalExpert Opinion on Investigational Drugs
Volume23
Issue number7
DOIs
StatePublished - Jul 2014
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Genes
Therapeutics
Phase III Clinical Trials
Phase II Clinical Trials
Clinical Trials, Phase I
Cytotoxins
Expert Testimony
Research
Cytogenetics
Leukemia
Drug Therapy
Mutation
Pharmaceutical Preparations

Keywords

  • Crenolanib
  • FMS-like tyrosine kinase 3 gene
  • FMS-like tyrosine kinase 3 gene inhibitor
  • Quizartinib
  • Sorafenib

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. / Pemmaraju, Naveen; Kantarjian, Hagop; Andreeff, Michael; Cortes, Jorge; Ravandi, Farhad.

In: Expert Opinion on Investigational Drugs, Vol. 23, No. 7, 07.2014, p. 943-954.

Research output: Contribution to journalReview article

Pemmaraju, Naveen ; Kantarjian, Hagop ; Andreeff, Michael ; Cortes, Jorge ; Ravandi, Farhad. / Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. In: Expert Opinion on Investigational Drugs. 2014 ; Vol. 23, No. 7. pp. 943-954.
@article{7d71fa0079d24606988d4a5321d80b19,
title = "Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia",
abstract = "Introduction: Outcomes for the majority of patients with acute myeloid leukemia (AML) remain poor. Over the past decade, significant progress has been made in the understanding of the cytogenetic and molecular determinants of AML pathogenesis. One such advance is the identification of recurring mutations in the FMS-like tyrosine kinase 3 gene (FLT3). Currently, this marker, which appears in approximately one-third of all AML patients, not only signifies a poorer prognosis but also identifies an important target for therapy. FLT3 inhibitors have now undergone clinical evaluation in Phase I, II and III clinical trials, as both single agents and in combination with chemotherapeutics. Unfortunately, to date, none of the FLT3 inhibitors have gained FDA approval for the treatment of patients with AML. Yet, several promising FLT3 inhibitors are being evaluated in all phases of drug development.Areas covered: This review aims to highlight the agents furthest along in their development. It also focuses on those FLT3 inhibitors that are being evaluated in combination with other anti-leukemia agents.Expert opinion: The authors believe that the field of research for FLT3 inhibitors remains promising, despite the historically poor prognosis of this subgroup of patients with AML. The most promising areas of research will likely be the elucidation of the mechanisms of resistance to FLT3 inhibitors, and development of potent FLT3 inhibitors alone or in combination with hypomethylating agents, cytotoxic chemotherapy or with other targeted agents.",
keywords = "Crenolanib, FMS-like tyrosine kinase 3 gene, FMS-like tyrosine kinase 3 gene inhibitor, Quizartinib, Sorafenib",
author = "Naveen Pemmaraju and Hagop Kantarjian and Michael Andreeff and Jorge Cortes and Farhad Ravandi",
year = "2014",
month = "7",
doi = "10.1517/13543784.2014.911839",
language = "English (US)",
volume = "23",
pages = "943--954",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia

AU - Pemmaraju, Naveen

AU - Kantarjian, Hagop

AU - Andreeff, Michael

AU - Cortes, Jorge

AU - Ravandi, Farhad

PY - 2014/7

Y1 - 2014/7

N2 - Introduction: Outcomes for the majority of patients with acute myeloid leukemia (AML) remain poor. Over the past decade, significant progress has been made in the understanding of the cytogenetic and molecular determinants of AML pathogenesis. One such advance is the identification of recurring mutations in the FMS-like tyrosine kinase 3 gene (FLT3). Currently, this marker, which appears in approximately one-third of all AML patients, not only signifies a poorer prognosis but also identifies an important target for therapy. FLT3 inhibitors have now undergone clinical evaluation in Phase I, II and III clinical trials, as both single agents and in combination with chemotherapeutics. Unfortunately, to date, none of the FLT3 inhibitors have gained FDA approval for the treatment of patients with AML. Yet, several promising FLT3 inhibitors are being evaluated in all phases of drug development.Areas covered: This review aims to highlight the agents furthest along in their development. It also focuses on those FLT3 inhibitors that are being evaluated in combination with other anti-leukemia agents.Expert opinion: The authors believe that the field of research for FLT3 inhibitors remains promising, despite the historically poor prognosis of this subgroup of patients with AML. The most promising areas of research will likely be the elucidation of the mechanisms of resistance to FLT3 inhibitors, and development of potent FLT3 inhibitors alone or in combination with hypomethylating agents, cytotoxic chemotherapy or with other targeted agents.

AB - Introduction: Outcomes for the majority of patients with acute myeloid leukemia (AML) remain poor. Over the past decade, significant progress has been made in the understanding of the cytogenetic and molecular determinants of AML pathogenesis. One such advance is the identification of recurring mutations in the FMS-like tyrosine kinase 3 gene (FLT3). Currently, this marker, which appears in approximately one-third of all AML patients, not only signifies a poorer prognosis but also identifies an important target for therapy. FLT3 inhibitors have now undergone clinical evaluation in Phase I, II and III clinical trials, as both single agents and in combination with chemotherapeutics. Unfortunately, to date, none of the FLT3 inhibitors have gained FDA approval for the treatment of patients with AML. Yet, several promising FLT3 inhibitors are being evaluated in all phases of drug development.Areas covered: This review aims to highlight the agents furthest along in their development. It also focuses on those FLT3 inhibitors that are being evaluated in combination with other anti-leukemia agents.Expert opinion: The authors believe that the field of research for FLT3 inhibitors remains promising, despite the historically poor prognosis of this subgroup of patients with AML. The most promising areas of research will likely be the elucidation of the mechanisms of resistance to FLT3 inhibitors, and development of potent FLT3 inhibitors alone or in combination with hypomethylating agents, cytotoxic chemotherapy or with other targeted agents.

KW - Crenolanib

KW - FMS-like tyrosine kinase 3 gene

KW - FMS-like tyrosine kinase 3 gene inhibitor

KW - Quizartinib

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84902340530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902340530&partnerID=8YFLogxK

U2 - 10.1517/13543784.2014.911839

DO - 10.1517/13543784.2014.911839

M3 - Review article

C2 - 24749672

AN - SCOPUS:84902340530

VL - 23

SP - 943

EP - 954

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 7

ER -